April 11, 2025

The American College of Radiology® (ACR®) provided comments to the U.S. Food and Drug Administration (FDA) regarding the agency’s draft guidance to address risk management approaches throughout the lifecycle of AI-enabled medical devices, including radiology AI. The document discusses information that manufacturers should share with FDA reviewers and other relevant stakeholders, including physicians and practices, to help them evaluate and monitor AI tools’ safety and effectiveness.

ACR’s comment letter supported the advancement of safe, effective, and clinically useful AI innovation. The College recommended further specificity in product information provided by manufacturers and regulators regarding clinical end-user qualifications. For example, radiologist end-users of imaging AI tools help mitigate risk because they are qualified to interpret imaging examinations without AI assistance. ACR also recommended various enhancements to the guidance’s content on site-level validation, performance monitoring and AI types with novel oversight considerations.  

For more information about ACR’s AI-related initiatives, visit the ACR DSI website. For questions about AI oversight and digital health policy, contact Michael Peters, ACR Senior Director, Government Affairs.


Related ACR News

  • Scope of Practice and Prior Authorization Bills Take Center Stage

    ACR tracks legislation at the state level that impacts radiologist and their patients.

    Read more
  • MedPAC Votes to Recommend PFS Annual Update at April Meeting

    MedPAC discussed issues relating to the Medicare and Medicare Advantage programs including concerns about updates applied to reimbursement.

    Read more
  • CMS Proposes 2.4% Update in FY 2026 Hospital IPPS Proposed Rule

    CMS releases the federal fiscal year (FY) 2026 Hospital Inpatient Prospective Payment System (IPPS) proposed rule.

    Read more